Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!
Mar 10, 2020
Soft tissue sarcoma- a rare tumor – accounting for less than 1% of all cancers – has the major unmet need in the form of limited treatment options for patients. Cytotoxic chemotherapy has been the mainstay of therapy for decades. Active drugs such as doxorubicin, ifosfamide, gemcitabine, taxanes, and several othe...
Read More...
Mar 06, 2020
What does a yellow ribbon signify? It symbolizes support for Sarcoma patients. Sarcoma – an umbrella term for several forms of cancer that occur in muscles or bones – is a rare form of cancer. There exist more than 70 types of sarcomas – mostly considered rare – classified on the basis of the type of tissue they af...
Read More...
Mar 07, 2019
Biogen to buy Nightstar for USD 800 Million Biogen known for its efforts in treatments of multiple sclerosis and spinal muscular atrophy wound up the deal to buy Nightstar. The deal will let Biogen have access to two experimental gene therapies for blindness-causing diseases helping Biogen’s pipeline. Pacira...
Read More...
Oct 23, 2018
Novartis comes up with an answer for breast cancer with PI3K drug alpelisib Novartis comes up with an answer with its recent data on BYL719 (alpelisib) in combination with fulvestrant. Their alpha-specific drug for PIK3CA mutated HR+/HER2- advanced breast cancer, BYL719 plus fulvestrant nearly doubled the progressio...
Read More...
Sep 25, 2018
The interleukin-33 antibody of AnaptysBio passes midstage test in asthma The pipeline drug, etokimab of AnaptysBio, has positive data in a third indication that adds asthma to one of its triumphs. The US-based company gets another proof-of-concept study for the interleukin-33 (IL-33) inhibitor, because of phase 2a ...
Read More...
Roche’s HER2-Positive Breast Cancer Treatment Franchise
Aug 13, 2024
Transforming Multiple Myeloma Treatment: The Promise of Novel Drug Classes
Jul 24, 2024
Newsletter/Whitepaper